Gastroenterology

Gastroenterology

Volume 120, Issue 3, February 2001, Pages 594-606
Gastroenterology

Gastroenterology 2001: Diagnostics & Therapeutics
Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient,☆☆

https://doi.org/10.1053/gast.2001.21907Get rights and content

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) are probably the most common cause of gastroduodenal injury in the United States today. Approximately half of patients who regularly take NSAIDs have gastric erosions, and 15%–30% have ulcers when they are examined endoscopically. However, the incidence of clinical gastrointestinal (GI) events caused by NSAIDs is much lower. Clinical upper GI events may occur in 3%–4.5% of patients taking NSAIDs, and serious complicated events develop in approximately 1.5%. However, the risk varies widely in relationship to clinical features such as history of ulcers or GI events, age, concomitant anticoagulant or steroid use, and NSAID dose. This review discusses the risks of clinical GI disease in NSAID users, the predictors of increased risk, and strategies for prevention of NSAID-associated GI disease.

GASTROENTROLOGY 2001;120:594-606

Section snippets

Endoscopic signs of injury

A single dose of aspirin leads to gross gastric injury in the form of subepithelial hemorrhages within 15–30 minutes of ingestion.5, 6, 7 Continued aspirin ingestion for 24 hours (650 mg 4 times a day) leads to the development of gastric erosions.5, 8 Virtually all subjects given aspirin develop these lesions in the first days of use.5, 8 However, subepithelial hemorrhages and erosions are mucosal lesions, whereas blood vessels of significant size are located in the submucosa or deeper. Thus,

Risk of clinical events

Only a small proportion of NSAID users develop GI complications. However, given the exceptionally widespread use of NSAIDs and aspirin, this small proportion translates into a large absolute number of NSAID users developing clinical GI events. A variety of epidemiologic studies (cohort and case-control) show a significant increase in clinical upper GI events with NSAID use (aspirin and nonaspirin NSAIDs), with most reports suggesting a 2–6-fold increase over the incidence in people not taking

Risk factors for NSAID-associated GI events

A variety of clinical factors have been reported to significantly increase the risk of developing NSAID-associated GI events. Important factors that are validated in multiple studies include history of ulcer or GI complications, increasing age, concomitant anticoagulation therapy, concomitant corticosteroid use, and high-dose NSAID use.

Risks with individual NSAIDs

NSAIDs inhibit prostaglandin production by inhibiting COX. Two isoforms of the COX enzyme are known to be involved in prostaglandin synthesis. COX-1 is constitutively expressed and generates prostaglandins involved in GI mucosal protection and platelet function, whereas COX-2 is induced at sites of inflammation to generate prostaglandins that mediate inflammation and pain. The anti-inflammatory effects of nonselective NSAIDs appear to be mediated via COX-2 inhibition, whereas the harmful

Strategies to decrease NSAID-associated GI events

Several strategies may be used to decrease the risk of NSAID-associated GI events. First, GI complications can be avoided by the use of non-NSAID analgesics, when possible. Second, use of the lowest effective dose of an NSAID will decrease the chance of complications. Third, medical cotherapy can be used in patients with increased risk of complications. Finally, the development of less injurious NSAIDs such as the COX-2–specific inhibitors will decrease the risk of GI events.

Economic considerations

Economic considerations are key in determining management of the GI risk in patients taking NSAIDs. The cost of NSAID-associated GI side effects is substantial. For example, using the Quebec health insurance database for 1993–1997, Rahme et al.83 estimated that for each dollar spent on NSAIDs, $0.66 is spent on their GI side effects. Using Medicaid data from Washington, D.C., for 1981–1983, Bloom84 found that 31% of the total cost of care for “arthritis” patients was for management of GI

Summary and recommendations

Endoscopic ulcers are found in ~15%–30% of patients who take NSAIDs regularly, but clinical GI events are relatively infrequent. Prospective outcome studies indicate an annual incidence of complicated GI events (perforation, obstruction, major bleeding) in arthritis patients of ~1.5% and an annual rate of all clinical GI events (complicated events plus ulcers discovered on work-up for significant GI symptoms) of ~3%–4.5%. Population cohort studies suggest that the annual rate of excess GI

References (90)

  • C Aalykke et al.

    Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory drugs: a case control study

    Gastroenterology

    (1999)
  • A Lanas et al.

    Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low dose aspirin (abstr)

    Gastroenterology

    (2000)
  • MJS Langman et al.

    Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs

    Lancet

    (1994)
  • B Cryer et al.

    Comparison of salsalate and aspirin on mucosal injury and gastroduodenal mucosal prostaglandins

    Gastroenterology

    (1990)
  • L Laine et al.

    A randomized double-blind comparison of placebo, etodolac, and naproxen on gastrointestinal injury and prostaglandin production

    Gastrointest Endosc

    (1995)
  • NM Agrawal et al.

    Comparison of the upper gastrointestinal safety of Arthrotec® 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers

    Clin Ther

    (1999)
  • P Emery et al.

    Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison

    Lancet

    (1999)
  • L Laine et al.

    Gastrointestinal (GI) co-therapy, procedures, and hospitalizations in a GI outcomes study of rofecoxib vs. naproxen in rheumatoid arthritis (abstr)

    Am J Gastroenterol

    (2000)
  • Retail & Provider Perspective, National Prescription Audit, 1999-2000

    (2000)
  • Infoscan Services, Internal Analgesics Category, Total Food, Drug and Mass Merch, 52 weeks ending July 16, 2000

    (2000)
  • Nonprescription drugs USA 1999, Internal Analgesics Product Category

    (1999)
  • NJ Talley et al.

    Nonsteroidal antiinflammatory drugs and dyspepsia in the elderly

    Dig Dis Sci

    (1995)
  • JC O'Laughlin et al.

    Effect of aspirin on the human stomach in normals: endoscopic comparison of damage produced one hour, 24 hours, and 2 weeks after administration

    Scand J Gastroenterol

    (1981)
  • DY Graham et al.

    Gastric adaptation occurs with aspirin administration in man

    Dig Dis Sci

    (1983)
  • JW Hoftiezer et al.

    Effects of 24 hours of aspirin, Bufferin, paracetamol and placebo on normal human gastroduodenal mucosa

    Gut

    (1982)
  • FL Lanza

    A review of gastric ulcer and gastroduodenal injury in normal volunteers receiving aspirin and other non-steroidal anti-inflammatory drugs

    Scand J Gastroenterol

    (1989)
  • C Hawkey et al.

    Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis. A randomized, double-blind, placebo-controlled trial

    Arthritis Rheum

    (2000)
  • LS Simon et al.

    Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. A randomized controlled trial

    JAMA

    (1999)
  • TM MacDonald et al.

    Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study

    BMJ

    (1997)
  • J Hallas et al.

    Non-steroidal anti-inflammatory drugs and upper gastrointestinal bleeding, identifying high-risk groups by excess risk estimates

    Scand J Gastroenterol

    (1995)
  • WE Smalley et al.

    Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons

    Am J Epidemiol

    (1995)
  • G Singh et al.

    NSAID induced gastrointestinal complications: the ARAMIS perspective-1997

    J Rheumatol

    (1998)
  • MR Griffin et al.

    Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons

    Ann Intern Med

    (1988)
  • FE Silverstein et al.

    Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial

    Ann Intern Med

    (1995)
  • F Silverstein et al.

    Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial

    JAMA

    (2000)
  • C Bombardier et al.

    Comparison of upper intestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis

    N Engl J Med

    (2000)
  • JH Kurata et al.

    The effect of chronic aspirin use on duodenal and gastric ulcer hospitalizations

    J Clin Gastroenterol

    (1990)
  • J Slattery et al.

    Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin-analysis of gastrointestinal bleeding during the UK-TIA trial

    Gut

    (1995)
  • J Weil et al.

    Prophylactic aspirin and risk of peptic ulcer bleeding

    BMJ

    (1995)
  • SE Gabriel et al.

    Risk for serious gastrointestinal complications related to the use of nonsteroidal anti-inflammatory drugs. A meta-analysis

    Ann Intern Med

    (1991)
  • LL Lanza et al.

    Peptic ulcer and gastrointestinal hemorrhage associated with nonsteroidal anti-inflammatory drug use in patients younger than 65 years. A large health maintenance organization cohort study

    Arch Intern Med

    (1995)
  • JM Hansen et al.

    Non-steroidal anti-inflammatory drugs and complications: a risk factor analysis for clinical decision-making

    Scand J Gastroenterol

    (1996)
  • RI Shorr et al.

    Daugherty JR, Griffin MR. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease

    Arch Intern Med

    (1993)
  • JM Piper et al.

    Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs

    Ann Intern Med

    (1991)
  • JL Carson et al.

    The association of nonsteroidal anti-inflammatory drugs with gastrointestinal tract bleeding

    Arch Intern Med

    (1987)
  • Cited by (0)

    Address correspondence to: Loren Laine, M.D., GI Division, Department of Medicine, University of Southern California School of Medicine, 2025 Zonal Avenue, Los Angeles, California 90033. e-mail: [email protected]; fax: (323) 226-7573.

    ☆☆

    Dr. Laine has been a consultant and received research support from various pharmaceutical companies whose medications are discussed in this article.

    View full text